New UK antibody firm to focus on COVID-19, viral infections

17 May 2022
biotech_lab_research_2022_big

Building on a licensing deal with AstraZeneca (LSE: AZN), British biotech RQ Biotechnology has announced its launch, with a focus on developing antibody treatments and preventive therapies.

The firm is working on developing broad-spectrum monoclonal antibodies to provide instant and long-lasting immunity for vulnerable people at risk from viral infections.

Starting with the novel coronavirus, the company is taking aim at existing, emerging and new viral infections, with the goal of stopping severe disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology